Inhibition of cyclin-dependent kinases by olomoucine and roscovitine reduces lipopolysaccharide-induced inflammatory responses via down-regulation of nuclear factor κb

Cell Proliferation

Volumn 42, Issue 2, 2009, Pages 141-149

  Jhou, R S ^a   Sun, K H ^c   Sun, G H ^d   Wang, H H ^b   Chang, C I ^e   Huang, H C ^a   Lu, S Y ^a   Tang, S J ^a  

^a NATIONAL TAIWAN OCEAN UNIVERSITY   (Taiwan)

^b CHENG HSIN REHABILITATION MEDICAL CENTER   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; COPPER ZINC SUPEROXIDE DISMUTASE; CYCLIN DEPENDENT KINASE; CYTOKINE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LUCIFERASE; MANGANESE SUPEROXIDE DISMUTASE; NITRIC OXIDE; OLOMOUCINE; ROSCOVITINE; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR RELA; TUBULIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; GENE EXPRESSION; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING;

ANIMALS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASES; DOWN-REGULATION; E2F1 TRANSCRIPTION FACTOR; ENZYME INHIBITORS; GENE EXPRESSION; INFLAMMATION; INTERLEUKIN-1ALPHA; INTERLEUKIN-6; KINETIN; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MODELS, BIOLOGICAL; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PROMOTER REGIONS, GENETIC; PURINES; RNA INTERFERENCE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

BACTERIA (MICROORGANISMS); MURINAE;

EID: 62449271079     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/j.1365-2184.2009.00584.x     Document Type: Article

References (36)

1. Vermeulen K, Van Bockstaele DR, Berneman ZN (2003a) The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 36, 131 149.
2. D'Souza SJ, Vespa A, Murkherjee S, Maher A, Pajak A, Dagnino L (2002) E2F-1 is essential for normal epidermal wound repair. J. Biol. Chem. 277, 10626 10632.
3. Muller H, Bracken AP, Vernell R, Moroni MC, Christians F, Grassilli E, Prosperini E, Vigo E, Oliner JD, Helin K (2001) E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. Genes Dev. 15, 267 285.
4. Stevaux O, Dyson NJ (2002) A revised picture of the E2F transcriptional network and RB function. Curr. Opin. Cell Biol. 14, 684 691.
5. Stevens C, La Thangue NB (2003) E2F and cell cycle control: a double-edged sword. Arch. Biochem. Biophys. 412, 157 169.
6. Vermeulen K, Berneman ZN, Van Bockstaele DR (2003b) Cell cycle and apoptosis. Cell Prolif. 36, 165 175.
7. Dai Y, Grant S (2003) Cyclin-dependent kinase inhibitors. Curr. Opin. Pharmacol. 3, 362 370.
8. Haesslein JL, Jullian N (2002) Recent advances in cyclin-dependent kinase inhibition. Purine-based derivatives as anti-cancer agents. Roles and perspectives for the future. Curr. Top. Med. Chem. 2, 1037 1050.
9. Alessi F, Quarta S, Savio M, Riva F, Rossi L, Stivala LA, Scovassi AI, Meijer L, Prosperi E (1998) The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity. Exp. Cell Res. 245, 8 18.
10. Hardcastle IR, Golding BT, Griffin RJ (2002) Designing inhibitors of cyclin-dependent kinases. Annu. Rev. Pharmacol. Toxicol. 42, 325 348.
11. Bain J, McLauchlan H, Elliott M, Cohen P (2003) The specificities of protein kinase inhibitors: an update. Biochem. J. 371, 199 204.
12. Boutis A, Papazisis K, Pistevou-Gompaki K, Lambropoulos A, Sofroniadis I, Papageorgiou A, Destouni E, Kortsaris A (2006) Cyclin-dependent kinase (CDK) inhibitor olomoucine enhances gamma-irradiation-induced apoptosis and cell cycle arrest in Raji cells. Anticancer Res. 26, 3493 3498.
13. Dey A, Wong ET, Cheok CF, Tergaonkar V, Lane DP (2008) R-Roscovitine simultaneously targets both the p53 and NF-κB pathways and causes potentiation of apoptosis: implications in cancer therapy. Cell Death Differ. 15, 263 273.
14. Rossi AG, Sawatzky DA, Walker A, Ward C, Sheldrake TA, Riley NA, Caldicott A, Martinez-Losa M, Walker TR, Duffin R, Gray M, Crescenzi E, Martin MC, Brady HJ, Savill JS, Dransfield I, Haslett C (2006) Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat. Med. 12, 1056 1064.
15. Calegari F, Huttner WB (2003) An inhibition of cyclin-dependent kinases that lengthens, but does not arrest, neuroepithelial cell cycle induces premature neurogenesis. J. Cell Sci. 116, 4947 4955.
16. Di Giovanni S, Movsesyan V, Ahmed F, Cernak I, Schinelli S, Stoica B, Faden AI (2005) Cell cycle inhibition provides neuroprotection and reduces glial proliferation and scar formation after traumatic brain injury. Proc. Natl. Acad. Sci. USA 102, 8333 8338.
17. Markus MA, Kahle PJ, Winkler A, Horstmann S, Anneser JM, Borasio GD (1997) Survival-promoting activity of inhibitors of cyclin-dependent kinases on primary neurons correlates with inhibition of c-Jun kinase-1. Neurobiol. Dis. 4, 122 133.
18. Monaco EA III, Beaman-Hall CM, Mathur A, Vallano ML (2004) Roscovitine, olomoucine, purvalanol: inducers of apoptosis in maturing cerebellar granule neurons. Biochem. Pharmacol. 67, 1947 1964.
19. Akira S, Takeda K (2004) Toll-like receptor signaling. Nat. Rev. Immunol. 4, 499 511.
20. Raetz CR, Whitfield C (2002) Lipopolysaccharide endotoxins. Annu. Rev. Biochem. 71, 635 700.
21. Bochud PY, Calandra T (2003) Pathogenesis of sepsis: new concepts and implications for future treatment. BMJ 326, 262 266.
22. Ulevitch RJ (2004) Therapeutics targeting the innate immune system. Nat. Rev. Immunol. 4, 512 520.
23. Karin M, Greten FR (2005) NF-κB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5, 749 759.
24. Smith PD, Ochsenbauer-Jambor C, Smythies LE (2005) Intestinal macrophages: unique effector cells of the innate immune system. Immunol. Rev. 206, 149 159.
25. Kawai T, Akira S (2006) TLR signaling. Cell Death Diff. 13, 816 825.
26. Guha M, Mackman N (2001) LPS induction of gene expression in human monocytes. Cell Signal 13, 85 94.
27. Tian B, Brasier AR (2003) Identification of a nuclear factor kappa B-dependent gene network. Recent Prog. Horm. Res. 58, 95 130.
28. Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, Young RA, Dynlacht BD (2002) E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev. 16, 245 256.
29. Ying L, Marino J, Hussain SP, Khan MA, You S, Hofseth AB, Trivers GE, Dixon DA, Harris CC, Hofseth LJ (2005) Chronic inflammation promotes retinoblastoma protein hyperphosphorylation and E2F1 activation. Cancer Res. 65, 9132 9136.
30. Peer D, Park EJ, Morishita Y, Carman CV, Shimaoka M (2008) Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 319, 627 630.
31. Lim C-A, Yao F, Wong j J-Y, George J, Xu Han Chiu KP (2007) Genome-wide mapping of RELA (p65) binding identifies E2F1 as a transcriptional activator recruited by NF-κB upon TLR4 activation. Mol. Cell 27, 622 635.
32. Kundu M, Guermah M, Roeder RG, Amini S, Khalili K (1997) Interaction between cell cycle regulator, E2F-1, and NF-κB mediates repression of HIV-1 gene transcription. J. Biol. Chem. 272, 29468 29474.
33. Tanaka H, Matsumura I, Ezoe S, Satoh Y, Sakamaki T, Albanese C, Machii T, Testell RG, Kanakura Y (2002) E2F1 and c-Myc potentiate apoptosis through inhibition of NF-κB activity that facilitates MnSOD-mediated ROS elimination. Mol. Cell 9, 1017 1029.
34. Tian DS, Yu ZY, Xie MJ, Bu BT, Witte OW, Wang W (2006) Suppression of astroglial scar formation and enhanced axonal regeneration associated with functional recovery in a spinal cord injury rat model by the cell cycle inhibitor olomoucine. J. Neurosci. Res. 85, 1053 1063.
35. Tian DS, Xie MJ, Yu ZY, Zhang Q, Wang YH, Chen B, Chen C, Wang W (2007) Cell cycle inhibition attenuates microglia induced inflammatory response and alleviates neuronal cell death after spinal cord injury in rats. Brain Res. 1135, 177 185.
36. Zhu Z, Zhang Q, Yu Z, Zhang L, Tian D, Zhu S, Bu B, Xie M, Wang W (2007) Inhibiting cell cycle progression reduces reactive astrogliosis initiated by scratch injury in vitro and by cerebral ischemia in vivo. Glia 55, 546 558.